ASRT vs. CUE, GNLX, ALLK, CTXR, IOBT, BYSI, ADAG, PMVP, ORMP, and RLMD
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Cue Biopharma (CUE), Genelux (GNLX), Allakos (ALLK), Citius Pharmaceuticals (CTXR), IO Biotech (IOBT), BeyondSpring (BYSI), Adagene (ADAG), PMV Pharmaceuticals (PMVP), Oramed Pharmaceuticals (ORMP), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Cue Biopharma (NASDAQ:CUE) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
Cue Biopharma has higher earnings, but lower revenue than Assertio. Cue Biopharma is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 10.2% of Cue Biopharma shares are owned by insiders. Comparatively, 3.2% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cue Biopharma presently has a consensus target price of $8.00, suggesting a potential upside of 406.33%. Assertio has a consensus target price of $5.50, suggesting a potential upside of 431.40%. Given Cue Biopharma's higher possible upside, analysts clearly believe Assertio is more favorable than Cue Biopharma.
Assertio has a net margin of -234.40% compared to Assertio's net margin of -711.84%. Cue Biopharma's return on equity of 10.80% beat Assertio's return on equity.
In the previous week, Assertio had 5 more articles in the media than Cue Biopharma. MarketBeat recorded 14 mentions for Assertio and 9 mentions for Cue Biopharma. Assertio's average media sentiment score of 0.92 beat Cue Biopharma's score of 0.76 indicating that Cue Biopharma is being referred to more favorably in the media.
Cue Biopharma received 39 more outperform votes than Assertio when rated by MarketBeat users. However, 59.09% of users gave Assertio an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Cue Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Summary
Assertio beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
